Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

New chelation strategy allows for quick and clean 99mTc-labeling of synthetic peptides.

Blok D, Feitsma HI, Kooy YM, Welling MM, Ossendorp F, Vermeij P, Drijfhout JW.

Nucl Med Biol. 2004 Aug;31(6):815-20.

PMID:
15246374
2.

Characterization of cereal toxicity for celiac disease patients based on protein homology in grains.

Vader LW, Stepniak DT, Bunnik EM, Kooy YM, de Haan W, Drijfhout JW, Van Veelen PA, Koning F.

Gastroenterology. 2003 Oct;125(4):1105-13.

PMID:
14517794
3.

Specificity of tissue transglutaminase explains cereal toxicity in celiac disease.

Vader LW, de Ru A, van der Wal Y, Kooy YM, Benckhuijsen W, Mearin ML, Drijfhout JW, van Veelen P, Koning F.

J Exp Med. 2002 Mar 4;195(5):643-9.

4.

Structure of celiac disease-associated HLA-DQ8 and non-associated HLA-DQ9 alleles in complex with two disease-specific epitopes.

Moustakas AK, van de Wal Y, Routsias J, Kooy YM, van Veelen P, Drijfhout JW, Koning F, Papadopoulos GK.

Int Immunol. 2000 Aug;12(8):1157-66.

PMID:
10917890
5.

The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase.

Arentz-Hansen H, Körner R, Molberg O, Quarsten H, Vader W, Kooy YM, Lundin KE, Koning F, Roepstorff P, Sollid LM, McAdam SN.

J Exp Med. 2000 Feb 21;191(4):603-12.

6.

Glutenin is involved in the gluten-driven mucosal T cell response.

van de Wal Y, Kooy YM, van Veelen P, Vader W, August SA, Drijfhout JW, Peña SA, Koning F.

Eur J Immunol. 1999 Oct;29(10):3133-9.

7.

Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin.

van de Wal Y, Kooy YM, van Veelen PA, Peña SA, Mearin LM, Molberg O, Lundin KE, Sollid LM, Mutis T, Benckhuijsen WE, Drijfhout JW, Koning F.

Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10050-4.

8.

Unique peptide binding characteristics of the disease-associated DQ(alpha 1*0501, beta 1*0201) vs the non-disease-associated DQ(alpha 1*0201, beta 1*0202) molecule.

van de Wal Y, Kooy YM, Drijfhout JW, Amons R, Papadopoulos GK, Koning F.

Immunogenetics. 1997;46(6):484-92.

PMID:
9321428
9.

Peptide binding characteristics of the coeliac disease-associated DQ(alpha1*0501, beta1*0201) molecule.

van de Wal Y, Kooy YM, Drijfhout JW, Amons R, Koning F.

Immunogenetics. 1996;44(4):246-53.

PMID:
8753854
10.

T-cell receptor usage of interleukin-2-responsive peripheral gamma delta T cells.

Orsini DL, Kooy YM, Van der Tol MA, Struyk L, Van den Elsen P, Koning F.

Immunology. 1995 Nov;86(3):385-91.

11.

Identification of two distinct function gamma delta TCR complexes on the surface of a human T cell clone.

Orsini DL, Kooy YM, Struyk L, Ossendorp F, Van den Elsen P, Koning F.

Scand J Immunol. 1995 May;41(5):499-503.

PMID:
7725069
12.

Functional and molecular characterization of B cell-responsive V delta 1+ gamma delta T cells.

Orsini DL, van Gils M, Kooy YM, Struyk L, Klein G, van den Elsen P, Koning F.

Eur J Immunol. 1994 Dec;24(12):3199-204.

PMID:
7528674
13.

A subset of V delta 1+ T cells proliferates in response to Epstein-Barr virus-transformed B cell lines in vitro.

Orsini DL, Res PC, Van Laar JM, Muller LM, Soprano AE, Kooy YM, Tak PP, Koning F.

Scand J Immunol. 1993 Oct;38(4):335-40.

PMID:
8210996

Supplemental Content

Support Center